Biogen Inc. (NASDAQ:BIIB) Q1 2026 Earnings Call Transcript - Insider Monkey
📈 Biogen reported Q1 2026 GAAP EPS of $2.15 (up 31% YoY) and non-GAAP EPS of $3.57 (up 18% YoY), beating analyst expectations of $3.05.
💰 Total revenue reached $2.5 billion, representing a 2% year-over-year increase driven by strong performance in growth products.
🧬 Growth product revenue totaled $851 million in the quarter, up 12% YoY, surpassing revenue from remaining multiple sclerosis (MS) products for the first time.
💉 LEQEMBI generated $168 million in Q1 revenue with a 74% year-over-year increase, maintaining its market leadership position in the U.S., Japan, and China.
👁️ SYFVORE achieved $151 million in global revenue (22% YoY growth), with ex-U.S. markets driving demand as the product expands into 35 countries.
💊 High-dose SPINRAZA has received approval in the U.S. and Europe, showing strong early adoption with 20% of patients converting to the new dosage regimen in Europe.
🤝 Biogen announced a proposed acquisition of Apellis Therapeutics, which is expected to close in Q2 2026 and be accretive to non-GAAP EPS starting in 2027.
💸 The company generated $594 million in free cash flow for the quarter while maintaining disciplined cost management with approximately $1.1 billion in core operating expenses.
🧪 New data from Salanersen demonstrated durable benefit over one year in children previously treated with gene therapy, with the first patient dosed in the pivotal STELLA-1 study.
🔬 Positive Phase II data were presented for Litifilimab in the ongoing AMITA study for systemic lupus erythematosus (SLE), reinforcing confidence in the late-stage pipeline.
📉 The company recorded approximately $34 million of acquired IP R&D charges in Q1 related to AltiGen and Alloy transactions, impacting GAAP EPS by roughly $0.20 per share.
🌍 Biogen acquired China rights for felzartamab (Empaveli) to expand its nephrology franchise and strengthen its presence in the world's second-largest pharmaceutical market.
📅 Upcoming catalysts include a PDUFA date of May 24 for LEQEMBI IQLIK initiation and multiple registrational data readouts expected later in 2026.
🧠 BIIB080, an antisense oligonucleotide targeting tau, is currently in a proof-of-concept study with results expected mid-year to evaluate clinical efficacy on cognition.
👥 Management highlighted strong patient persistence for LEQEMBI, with nearly 80% of patients remaining on therapy at 18 months and almost 70% at two years.
🏭 Biogen expects to fund the Apellis acquisition using $3.6 billion in cash and $2 billion in bank borrowings, planning to repay the debt by the end of 2027.
- Biogen reported Q1 2026 GAAP EPS of $3.57, significantly beating analyst expectations of $3.05.
- Growth products generated $851 million in revenue for the quarter, representing a strong 12% year-over-year increase.
- LEQEMBI market revenue surged 74% year-over-year to $168 million, maintaining its position as the market leader in the U.S., Japan, and China.
- SKYCLARYS demonstrated robust demand growth with global revenue of $151 million, up 22% year-over-year, now available in 35 countries.
- Real-world data for LEQEMBI shows strong treatment persistence, with nearly 80% of patients remaining on therapy at 18 months and almost 70% at 2 years.
- The high-dose SPINRAZA received approval in the U.S. and Europe, showing immediate traction with 20% of European patients converting to the new dosage regimen.
- Biogen generated $594 million in free cash flow for the quarter, providing ample liquidity to fund growth initiatives and the upcoming Apellis acquisition.
- The company exited Q1 with a strong balance sheet of $4.7 billion in cash and marketable securities.
- The proposed Apellis transaction is expected to be accretive to non-GAAP EPS in 2027, materially increasing the long-term EPS outlook.
- Biogen acquired China rights for felzartamab, expanding its presence in the world's second-largest pharmaceutical market and enhancing its nephrology franchise.
- The first patient has been dosed in the pivotal STELLA-1 study for Salanersen, a milestone that triggers an expected $0.25 per share impact in Q2 2026.
- Litifilimab received breakthrough designation for CLE and presented positive Phase II data, reinforcing confidence in the late-stage pipeline.
- The company expects to see multiple registrational data readouts starting later this year through the end of the decade, strengthening the growth outlook.
- Biogen recorded approximately $34 million of acquired IP R&D charges in Q1 2026 related to the AltiGen and Alloy transactions, resulting in an approximate $0.20 per share impact to GAAP and non-GAAP EPS.
- In Q1 2025, Biogen recorded $165 million of acquired IP R&D associated with upfront payments for ZOREVUNERSEN, which resulted in an approximately $0.95 per share impact to GAAP and non-GAAP EPS.
- Biogen expects to incur approximately $145 million or an $0.80 per share impact from acquired IP R&D charges in Q2 2026 related to the TJ Bio transaction for felzartamab rights in China.
- The first patient dosed in the pivotal STELLA-1 study for Salanersen triggered a milestone in Q2 2026, resulting in an approximately $0.25 per share impact.
- The company plans to fund the Apellis acquisition with $2 billion from new bank borrowings, which it expects to repay by the end of 2027.
- SKYCLARYS Q1 2026 revenue was impacted by inventory dynamics and moderate growth in demand in the U.S., with ex-U.S. growth expected to come later as reimbursement is negotiated.
- The BIIB080 Phase II trial was downsized from 700 patients to approximately 400 patients, reflecting a reduction in study scale.
- Competitive pressure exists for SYFOVRE from other agents targeting C5 (such as Annexon and Regeneron) that focus on visual acuity outcomes rather than lesion burden.
- Annexon's Phase II data did not impact geographic atrophy lesion growth, which Biogen considers the gold standard for efficacy assessment.
- Soliris, a competitor with a similar mechanism of action to SYFOVRE, failed in Phase II trials for geographic atrophy.
- The BIIB080 trial is pioneering with no precedent, requiring discovery of the right patient population and duration of tau reduction needed for cognitive benefit.
- SKYCLARYS patients tend to be slower progressors and older than initially predicted, which may extend the time required to find them and generate revenue.
- Biogen has not yet closed the Apellis transaction, so consolidated guidance for 2026 inclusive of the deal is not provided until after the close.
- The BIIB080 trial data readout is expected mid-year, introducing uncertainty regarding whether the study will demonstrate clinical efficacy on cognition.
